fda compounding semaglutide crackdown news today The is cracking down on ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety, FDA proposes curbs on mass

In fact, Wegovy has not even been brought to market in Canada, driving patients and their clinicians to use Ozempic off-label for therapeutic weight loss in obesity, and still others for so-called vanity weight loss

It should only be taken by people enrolled in an authorised clinical trial, under the supervision of a qualified clinician

A reduced appetite is commonly noticed within the first week, which is one of the earliest signs that the medication is beginning to work

Translational Oncol

Next, patients meet with their provider via video visit to review the lab results and answer any additional questions their provider may have to inform a personalized treatment plan

The FDA proposed in April 2026 to exclude semaglutide and tirzepatide from the 503B compounding bulks list - a development with real program availability implications that needs a direct answer from IVY RX before you commit to a multi-month plan